442 related articles for article (PubMed ID: 31903112)
21. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
Wu YL; Soo RA; Locatelli G; Stammberger U; Scagliotti G; Park K
Cancer Treat Rev; 2017 Dec; 61():70-81. PubMed ID: 29121501
[TBL] [Abstract][Full Text] [Related]
22. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Hage C; Rausch V; Giese N; Giese T; Schönsiegel F; Labsch S; Nwaeburu C; Mattern J; Gladkich J; Herr I
Cell Death Dis; 2013 May; 4(5):e627. PubMed ID: 23661005
[TBL] [Abstract][Full Text] [Related]
23. The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
Bai Z; Du Y; Cong L; Cheng Y
Gene; 2020 Oct; 758():144960. PubMed ID: 32687947
[TBL] [Abstract][Full Text] [Related]
24. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
[TBL] [Abstract][Full Text] [Related]
25. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
Luna J; Boni J; Cuatrecasas M; Bofill-De Ros X; Núñez-Manchón E; Gironella M; Vaquero EC; Arbones ML; de la Luna S; Fillat C
Gut; 2019 Aug; 68(8):1465-1476. PubMed ID: 30343272
[TBL] [Abstract][Full Text] [Related]
26. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Alagesan B; Contino G; Guimaraes AR; Corcoran RB; Deshpande V; Wojtkiewicz GR; Hezel AF; Wong KK; Loda M; Weissleder R; Benes CH; Engelman J; Bardeesy N
Clin Cancer Res; 2015 Jan; 21(2):396-404. PubMed ID: 25348516
[TBL] [Abstract][Full Text] [Related]
27. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
[TBL] [Abstract][Full Text] [Related]
28. Theranostic application of
Li C; Liu J; Yang X; Yang Q; Huang W; Zhang M; Zhou D; Wang R; Gong J; Miao Q; Kang L; Yang J
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):168-183. PubMed ID: 36063202
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy.
Tomihara H; Yamada D; Eguchi H; Iwagami Y; Noda T; Asaoka T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Cancer Sci; 2017 Mar; 108(3):398-407. PubMed ID: 28064436
[TBL] [Abstract][Full Text] [Related]
30. Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library.
Mortazavi M; Raufi E; Damghani T; Khoshneviszadeh M; Edraki N; Eskandari M; Giovannetti E; Peters GJ; Pirhadi S; Firuzi O
Eur J Pharmacol; 2023 Jan; 938():175395. PubMed ID: 36410418
[TBL] [Abstract][Full Text] [Related]
31. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
32. Radiation-Activated Cobalamin-Kinase Inhibitors for Treatment of Pancreatic Ductal Adenocarcinoma.
Gendron LN; Sheveland CG; Gunn JR; Pogue BW; Shell TA; Shell JR
Mol Pharm; 2024 Jan; 21(1):137-142. PubMed ID: 37989273
[TBL] [Abstract][Full Text] [Related]
33. Cadherin-17 as a target for the immunoPET of adenocarcinoma.
Delaney S; Keinänen O; Lam D; Wolfe AL; Hamakubo T; Zeglis BM
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38625402
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
35. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.
Zhou W; Jubb AM; Lyle K; Xiao Q; Ong CC; Desai R; Fu L; Gnad F; Song Q; Haverty PM; Aust D; Grützmann R; Romero M; Totpal K; Neve RM; Yan Y; Forrest WF; Wang Y; Raja R; Pilarsky C; de Jesus-Acosta A; Belvin M; Friedman LS; Merchant M; Jaffee EM; Zheng L; Koeppen H; Hoeflich KP
J Pathol; 2014 Dec; 234(4):502-13. PubMed ID: 25074413
[TBL] [Abstract][Full Text] [Related]
36. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
37. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
Henry KE; Dacek MM; Dilling TR; Caen JD; Fox IL; Evans MJ; Lewis JS
Clin Cancer Res; 2019 Jan; 25(1):166-176. PubMed ID: 30228208
[TBL] [Abstract][Full Text] [Related]
38. Radiation-Induced Autophagy in Human Pancreatic Cancer Cells is Critically Dependent on G2 Checkpoint Activation: A Mechanism of Radioresistance in Pancreatic Cancer.
Suzuki M; Anko M; Ohara M; Matsumoto KI; Hasegawa S
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):260-271. PubMed ID: 34112559
[TBL] [Abstract][Full Text] [Related]
39. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the SLC35B2-TPST2 Axis of Tyrosine Sulfation Attenuates the Growth and Metastasis of Pancreatic Ductal Adenocarcinom.
Cai X; Li S; Zeng X; Xu M; Wang Z; Singhi AD; Tang D; Li S; Yates NA; Yang D; Xie W
Cell Mol Gastroenterol Hepatol; 2023; 16(3):473-495. PubMed ID: 37192689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
